Advertise with us

World Pharma News is the leader in coverage of the most prominent pharmaceutical news.

Be featured on World Pharma News!

Want to place your Ads or News on World Pharma News?

World Pharma News is the leader in coverage of the most prominent pharmaceutical news. Advertising on World Pharma News is a smart choice for your business.

World Pharma News is one of the most visited sites on the Internet for pharmaceutical business decision-makers, professionals and stakeholders looking for the latest breaking news on the global market and in-depth research news articles. Why not put this traffic to work for you? It costs only a fraction of other on-line publications, which have far fewer readers.

We have the solutions that meet your ambitious marketing objectives. We offer flexible and price-worthy advertising opportunities for you to take advantage of. These include:

  • Skyscraper Banner, 120px / 600px (left-top, left-bottom)
  • Medium Rectangle Banner, 300px / 250px (right-top, medium and right-bottom)
  • Standard Banner, 468px / 60px (middle-top and middle-bottom)
  • Leaderboard Banner, 728px / 90px (top and bottom)
  • Newsletter Ads

The strong, innovative capabilities of World Pharma News can support your advertising, news promotion and news distribution campaigns. You will reach your objectives and an unique audience of top pharma professionals, key players and decision makers.

Don't Be Shy. If we didn’t answer all of your questions, feel free to drop us a line anytime.

Get In Touch

Facebook +19K

Twitter +60K

LinkedIn +6K

XING +7K

RSS +4K

Newsletter Subscribers +7K

Page Views +20K

FREE

Limited availability!

  • One News / Press Release publication
  • One News / Press Release publication in weekly Newsletter
  • News / Press Release featured on the first page
  • Posted to all social networks
  • Multimedia content
  • Web links
  • $0

PREMIUM

Everything you need!

  • One News / Press Release publication
  • One News / Press Release publication in weekly Newsletter
  • News / Press Release featured on the first page
  • Posted to all social networks
  • Multimedia content
  • Web links
  • Company Profile
  • $19.99

STANDARD

Great for your news!

  • One News / Press Release publication
  • One News / Press Release publication in weekly Newsletter
  • News / Press Release featured on the first page
  • Posted to all social networks
  • Multimedia content
  • Web links
  • $9.99

World Pharma News reserves the right to refuse to publish any news, press release for any reason.

Most Popular Now

Cannabis extract helps reset brain function in psy…

Research from King's College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psyc...

For first time in 40 years, cure for acute leukemi…

Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemi...

New cancer treatment uses enzymes to boost immune …

Researchers at The University of Texas at Austin have developed a new approach to treating cancer using enzyme therapy. The enzyme, PEG-KYNase, does not directly kill can...

Bayer accelerates six new startups

Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies fr...

Novartis receives European Commission approval of …

Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pe...

Shire completes sale of oncology franchise

Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it has completed the sale of its Oncology franchise to Servier S.A.S. for $2.4 billion. The franchise includes the...

Antioxidant reduces risk for second heart attack, …

Doctors have long known that in the months after a heart attack or stroke, patients are more likely to have another attack or stroke. Now, a paper in the Journal of the A...

Novartis to divest the Sandoz US dermatology busin…

Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids po...

SOLAR-1 trial of Novartis investigational alpha-sp…

Novartis today announced the global Phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) has met the primary endpoint s...

New tablet production facility in Ingelheim: Cente…

Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on ...

Tezepelumab granted Breakthrough Therapy Designati…

AstraZeneca and its partner Amgen Inc. (Amgen) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab...

Pfizer terminates domagrozumab (PF-06252616) clini…

Pfizer Inc. (NYSE: PFE) announced that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrop...